Amphastar (AMPH) Q4 2025 earnings review
A Painful Transition: Legacy Generics Bleed Faster Than Branded Growth
Amphastar's Q4 results expose the friction of its strategic pivot. The company is actively transitioning away from a legacy generic portfolio toward branded and complex proprietary products. However, the legacy business is deteriorating rapidly. Glucagon sales collapsed 45% as cheaper competitors flooded the market, dragging Total Revenue down 2% YoY to $183.1M. While BAQSIMI and new pipeline launches provided a cushion, they couldn't prevent a severe profitability squeeze: Adjusted Net Income fell 28% YoY to $34.2M as operating expenses surged to support R&D and internal infrastructure.
🐂 Bull Case
BAQSIMI revenue increased 12% YoY to $46.7M in Q4. Amphastar now fully controls the global distribution and is utilizing its sales force to expand market penetration.
The long-awaited pipeline is finally generating revenue. Recently launched Albuterol and Iron Sucrose (August 2025) added $6.2M in combined incremental Q4 sales, providing a new growth vector.
🐻 Bear Case
The Glucagon and Epinephrine portfolios are facing intense pricing and volume pressure. Glucagon sales dropped an alarming 45% YoY in Q4, and management has limited levers to stop the erosion.
Operating leverage is Reversing. Gross margins are squeezed by lower pricing on legacy products, while R&D and G&A expenses are growing near 30% YoY, punishing the bottom line.
⚖️ Verdict: 🔴
Bearish. The long-term vision of a proprietary-led portfolio makes strategic sense, but the near-term financial reality is grim. The core generic business is eroding too quickly for new assets to seamlessly bridge the gap, leading to contracting margins and falling earnings.
Key Themes
The Glucagon and Epinephrine Freefall
Decelerating. Amphastar's legacy critical care products are in a steep decline. Q4 Glucagon sales plummeted 45% YoY to $14.1M due to severe pricing pressure and a market shift toward ready-to-use alternatives. Epinephrine followed suit, falling 9% to $17.1M due to lower pricing on multi-dose vials. The transition away from these cash cows is proving highly disruptive to near-term earnings.
Primatene MIST Reverses Course
Reversing. After quarters of steady, reliable growth that anchored the branded portfolio, Primatene MIST sales declined 3% YoY in Q4 to $27.9M. Management attributed this to lower unit volumes. If this former growth engine stalls, Amphastar will become dangerously reliant on BAQSIMI to offset its generic declines.
New Product Launches Beginning to Scale
Accelerating. The 'Other products' segment was the brightest spot in the quarter, growing 8% YoY to $62.4M. This was driven primarily by the recent commercialization of the pipeline: Albuterol added $4.2M and Iron Sucrose added $2.0M. With the recent FDA approval of teriparatide injection, this segment should continue to act as a vital growth driver in 2026.
Runaway Operating Expenses
Decelerating profitability. While gross margins slightly stabilized sequentially, operating expenses are ballooning. R&D jumped 29% YoY to $23.3M due to clinical trials for insulin and inhalation products. G&A surged 27% to $16.5M, driven by legal expenses and a new ERP system implementation. This heavy spending against a shrinking revenue base caused Q4 GAAP net income to drop 36%.
Strategic Pivot into Novel Therapies
Amphastar is fundamentally changing its DNA. Beyond complex generics, the company in-licensed three novel peptides and a fully synthetic corticotropin compound this year. This expands their total addressable market into oncology, ophthalmology, and immunology, representing a high-risk, high-reward bet on becoming a true innovator rather than just a generic manufacturer.
Other KPIs
Decelerating. Down 28% YoY from $47.2 million in 24Q4. The drop reflects the brutal combination of losing high-margin generic revenue (Glucagon) and absorbing significant double-digit increases in R&D and administrative overhead.
Stable. Despite the net income pressure, Amphastar continues to generate healthy cash flows, down only moderately from the $213.4 million generated in FY24. This cash is essential to self-fund their aggressive U.S. manufacturing expansion and ongoing share repurchases.
Accelerating. An increase of 29% YoY. Management noted this is primarily driven by clinical trial expenses related to their insulin and inhalation pipeline products, signaling that elevated R&D spending is structural as they advance complex biosimilars.
Guidance
Stable. The company currently has one ANDA and one biosimilar insulin candidate filed with the FDA. This represents the immediate addressable market they aim to unlock to offset legacy generic declines.
Stable. Amphastar highlighted two biosimilar products targeting a >$3.7B market, and two generic products targeting a >$1.0B market in their active development pipeline, emphasizing the long-term scale of their transition.
Key Questions
BAQSIMI Sequential Deceleration
BAQSIMI sales dropped from $53.6 million in Q3 to $46.7 million in Q4. Was this driven by seasonal channel dynamics, or is the market penetration rate slowing despite the MannKind co-promotion agreement?
Primatene MIST Reversal
After consistent historical growth and surpassing the $100M annual milestone last year, Primatene MIST unit volumes and revenue declined in Q4. Is this a temporary fluctuation, or are we seeing a ceiling on OTC demand?
Operating Expense Run-Rate
With the 27% increase in G&A driven partly by the new ERP system, and a 29% increase in R&D, should investors view Q4's elevated OpEx base as the new structural normal for 2026?
Glucagon Floor
Glucagon sales plummeted 45% YoY. At what revenue level do you anticipate this product finding a stable floor, and are you actively stepping away from specific low-margin contracts?